Winslow Evans & Crocker’s VanEck Pharmaceutical ETF PPH Stock Holding History

Winslow Evans & Crocker’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100	Closed	-$5.91K	–	1223
2017 Q2	$5.91K	Hold	100	–	–	﹤0.01%	1029
2017 Q1	$5.51K	Hold	100	–	–	﹤0.01%	1018
2016 Q4	$5.25K	Hold	100	–	–	﹤0.01%	1022
2016 Q3	$5.75K	Hold	100	–	–	﹤0.01%	1032
2016 Q2	$5.86K	Hold	100	–	–	﹤0.01%	997
2016 Q1	$5.75K	Hold	100	–	–	﹤0.01%	994
2015 Q4	$6.53K	Hold	100	–	–	﹤0.01%	1001
2015 Q3	$6.3K	Hold	100	–	–	﹤0.01%	978
2015 Q2	$7.08K	Hold	100	–	–	﹤0.01%	1009
2015 Q1	$7.02K	Hold	100	–	–	﹤0.01%	965
2014 Q4	$6.43K	Hold	100	–	–	﹤0.01%	984
2014 Q3	$6.36K	Hold	100	–	–	﹤0.01%	1010
2014 Q2	$6.2K	Hold	100	–	–	﹤0.01%	976
2014 Q1	$5.84K	Buy	+100	New	+$5.66K	﹤0.01%	986

Other funds holding PPH

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winslow Evans & Crocker's PPH Position: Q3 2017 in Review

Winslow Evans & Crocker sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2017, closing a stake of 100 shares — an estimated $5.91K sold.

Winslow Evans & Crocker first reported a position in PPH in Q1 2014 and held it in 14 quarters. The position peaked at $7.08K in Q2 2015. 48 funds tracked by Wall St. Rank hold PPH as of Q3 2017.

Winslow Evans & Crocker reported no remaining VanEck Pharmaceutical ETF position as of Q3 2017 after selling out during the quarter.
Winslow Evans & Crocker sold 100 VanEck Pharmaceutical ETF shares in Q3 2017, an estimated $5.91K.
Winslow Evans & Crocker first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and held it in 14 quarters.
Winslow Evans & Crocker's VanEck Pharmaceutical ETF position peaked at $7.08K in Q2 2015.
48 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2017.

Based on Winslow Evans & Crocker's 13F filing for Q3 2017, filed 19 Oct 2017.